Application of Methods for Health Technology Assessment
Tuesday June 23, 2015, Allschwil (Basel)
Presentations and Slides
The importance of Health Technology Assessment (HTA) has increased substantially over the last few years. In order to obtain reimbursement, it has become critical for manufacturers to provide additional evidence about their products in a real-world setting to satisfy the requirements of the various national HTA bodies and best guide internal decision-making post market authorization.
The Basel Biometric Society (BBS) and the European Federation of Statisticians in the Pharmaceutical Industry (EFSPI) organized a European Scientific Meeting on this relevant topic. The meeting provided a forum to hear about the latest development of methods in the applications of HTA from representatives from European regulatory bodies, and from practitioners in the pharmaceutical industry and academia.